# Evaluation of Conjugated VesiVax Formulations for HIV Vaccines

> **NIH NIH N43** · MOLECULAR EXPRESS, INC. · 2020 · $299,961

## Abstract

Co-delivery and Formulation of Adjuvants for HIV Vaccine Development: Co-delivery of adjuvants with HIV antigens combined with HIV immunogen design is not mutually exclusive and should converge to accelerate the development of safe and effective adjuvanted HIV vaccine candidates that are capable of effective B/T-cell activation, enhanced antibody avidity or broadening of effector immune responses while minimizing reactogenicity and preserving the protective immune responses against HIV. The primary goal is to support, accelerate and advance early stage and/or pre-clinical development and optimization of a promising HIV antigen-adjuvant formulation or select combination-adjuvant(s) for co-delivery/co-administration for a preventative HIV vaccine.

## Key facts

- **NIH application ID:** 10214865
- **Project number:** 75N93020C00010-0-9999-1
- **Recipient organization:** MOLECULAR EXPRESS, INC.
- **Principal Investigator:** SAM ON HO
- **Activity code:** N43 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $299,961
- **Award type:** —
- **Project period:** 2020-06-01 → 2021-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10214865

## Citation

> US National Institutes of Health, RePORTER application 10214865, Evaluation of Conjugated VesiVax Formulations for HIV Vaccines (75N93020C00010-0-9999-1). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10214865. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*